These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5125051)

  • 1. [Combined treatment of parkinsonian syndromes with amantadine and gamma hydroxybutyric acid].
    Ferrari W; Rossini R; Bonasegla F; Boncinelli A; Prandi G; Greggia A
    Minerva Med; 1971 Oct; 62(82):3958-9. PubMed ID: 5125051
    [No Abstract]   [Full Text] [Related]  

  • 2. [Preliminary results of the use of gamma-hydroxybutyric acid in parkinsonian syndromes].
    Greggia A; Casalgrandi L; Boncinelli A; Prandi G
    Riv Sper Freniatr Med Leg Alien Ment; 1971 Apr; 95(2):412-9. PubMed ID: 5091480
    [No Abstract]   [Full Text] [Related]  

  • 3. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes].
    Kluzer G; Lampo B
    Minerva Med; 1971 Oct; 62(82):4013-4. PubMed ID: 5125067
    [No Abstract]   [Full Text] [Related]  

  • 4. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes and their implications for rehabilitation].
    Raspa EG; Paciaroni E; Saccomanno G
    Minerva Med; 1971 Oct; 62(82):4031-5. PubMed ID: 5125073
    [No Abstract]   [Full Text] [Related]  

  • 5. [Data on the therapeutic action of amantadine in parkinsonian syndromes].
    Barone A; Gentile A; Scoleri G
    Minerva Med; 1971 Oct; 62(82):3979-83. PubMed ID: 5125058
    [No Abstract]   [Full Text] [Related]  

  • 6. [Preliminary results of the use of amantadine in parkinsonian syndromes].
    Montanari M; Monaco V; Robotti CA
    Minerva Med; 1971 Oct; 62(82):3955-7. PubMed ID: 5125050
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa].
    Ambrosetto C; Martinelli P
    Minerva Med; 1971 Oct; 62(82):4017-9. PubMed ID: 5125069
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacologico-clinical trials of the association of L-dopa and gamma-hydroxybutyric acid in therapy of Parkinson's disease].
    Ferrari M; Furlanut M; Battistin L; Benedetti A; Mingrino S
    Clin Ter; 1971 May; 57(4):351-6. PubMed ID: 5110949
    [No Abstract]   [Full Text] [Related]  

  • 9. [Psychotic reactions in parkinsonian patients treated with amantadine].
    Fernández Martín F
    Rev Clin Esp; 1970 Aug; 118(4):371-2. PubMed ID: 5486104
    [No Abstract]   [Full Text] [Related]  

  • 10. [Preliminary psychological findings during treatment of the parkinsonian syndrome with amantadine. Preliminary observations].
    Barbieri NF; Megna GF; Micalizzi V; Pigneri MT; Puca FM
    Minerva Med; 1971 Oct; 62(82):4000-3. PubMed ID: 5125063
    [No Abstract]   [Full Text] [Related]  

  • 11. [Amantadine in the therapy of Parkinson syndromes].
    Pfaff G
    Med Klin; 1980 Oct; 75(22):792-4. PubMed ID: 7453628
    [No Abstract]   [Full Text] [Related]  

  • 12. [Action of amantadine on parkinsonian tremor].
    Agnoli A; Casacchia M; Ruggieri S; Volante F; Accornero N
    Minerva Med; 1971 Oct; 62(82):3990-3. PubMed ID: 5125061
    [No Abstract]   [Full Text] [Related]  

  • 13. [On the palm-chin reflex in parkinsonian patients treated with L-adamantyl-amine hydrochloride (amantadine)].
    Loria G; D'Arrigo G; Di Stefano F
    Riv Neurobiol; 1971; 17(3):379-87. PubMed ID: 5156133
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of amantadine sulfate as a infusion solution in the treatment of parkinsonian syndrome].
    Muschard F; Völler GW
    Med Welt; 1973 Feb; 24(5):183-4. PubMed ID: 4617092
    [No Abstract]   [Full Text] [Related]  

  • 15. [The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
    Shiozawa R; Kase M; Kuroiwa Y; Narabayashi H; Nishitani Y; Ohmoto T; Toyokura Y; Uono K
    No To Shinkei; 1981 Mar; 33(3):301-9. PubMed ID: 7018522
    [No Abstract]   [Full Text] [Related]  

  • 16. [Long-term effects of amantadine in striatal syndromes].
    Rovetta P
    Minerva Med; 1971 Oct; 62(82):3965-7. PubMed ID: 5125054
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of 1-adamantil-amine chlorhydrate on parkinsonian asynkinesia].
    Megna G
    Acta Neurol (Napoli); 1971; 26(6):701-6. PubMed ID: 4946490
    [No Abstract]   [Full Text] [Related]  

  • 18. [Medical treatment of Parkinson's disease with amantadine hydrochloride. Preliminary note].
    Portera A; Varela de Seijas E; Mata P; Ramírez Echevarría TJ; Amaya Pombo C
    Rev Clin Esp; 1970 Jun; 117(6):579-86. PubMed ID: 5518942
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of amantadine in the treatment of parkinsonism].
    D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A
    Minerva Med; 1971 Oct; 62(82):3952-4. PubMed ID: 5125049
    [No Abstract]   [Full Text] [Related]  

  • 20. Amantadine in Parkinson's disease: pro and contra.
    Greulich W; Fenger E
    J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.